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Synthesis, Characterization and Biological Evaluation of Novel (S,E)-11-[2-(Arylmethylene) 
Hydrazono] Pyrrolo [2,1-c] [1,4] Benzodiazepine Derivatives 
by  
David Mingle 
Pyrrolo [2,1-c] [1,4] benzodiazepine (PBD) is a class of natural products obtained from various 
actinomycetes which have both anti-tumor and antibiotic activities and can bind to specific 
sequences of DNA. PBD-dilactam was initially produced using isatoic anhydride and (L)-proline 
which was then converted to the PBD-thiolactam using Lawesson's reagent. Reaction of 
thiolactam with hydrazine in ethanol afforded PBD-11-hydrazinyl. Condensation of 11-
hydrazinyl PBD with aldehydes possessing various substitutions was performed to obtain (S,E)-
11-[2-(arylmethylene) hydrazono] pyrrolo [2,1-c] [1,4] benzodiazepine derivatives. 1HNMR, 
13C-NMR, DEPT, IR, GC-MS and X-ray crystallography were used for the characterization. 
Inhibition activity of the products were carried out using TEM-1, AmpC and P99 β-lactamases. 
A minimal inhibition growth of 25% was observed for one of the selected PBDs on cancer cell 
line. A promising result was observed on preliminary cannabinoid binding activity test on one of 
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Natural Products  
There is an abundance of organic compounds provided by nature which we call natural 
products. There are two types of metabolites obtained from natural products which are primary 
and secondary. Primary metabolites are directly involved in growth and metabolism examples 
include carbohydrates, proteins, and lipids. Secondary metabolites are not directly involved in 
the growth and development of organic compounds.1 Alkaloids are one of the largest groups of 
organic compounds that have cyclic structure and nitrogen atom in its core structure. They have a 
wide range of properties some of which include a defense mechanism (chemical) against 
microbes and herbivores that includes sheep, cow, and elephant. Alkaloids are used as 
medications because of their pharmacological effects. Morphine, caffeine, nicotine, and quinine 
are some examples of alkaloids that have medicinal properties. Many alkaloids contain other 
functional groups that give them the ability to interact with biological targets of interest.1,2 
 
Pyrrolo[2,1-c] [1,4] benzodiazepines 
In 1960, Streptomyces species were found to contain Pyrrolo[2,1-c] [1,4] 
benzodiazepines (PBDs). PBDs were first isolated and synthesized from Streptomyces refuineus, 
and this was done in the laboratory by Leimgruber et al.3 After the isolation of anthramycin (12, 
Figure 1) from cultures of Streptomyces.4 The three isomers of pyrrolo[2,1c] 
[1,4]benzodiazepines (Figure 1) have been thoroughly studied and the other important PBDs 
isolated from Streptomyces species are tomaymycin, sibiromycin, neothramycins and DC-81.5 
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Their mechanism of action depends on the right-handed helical conformation because of their 
(S)-configuration at C-11a found from an X-ray crystal structure analysis of anthramycin (12)6 
which facilitates the molecules to fit in the minor groove of DNA selectivity at the 51-purine-G-


























  Chicamycin A   Abbeymycin16 17  
Figure 1. Structure of the three pyrrolo [1,4] benzodiazepine isomers 9–11 and the derivatives 
                 12-17 
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Of all the natural products, anthramycin was very promising because it was active against a wide 
range of cancers. Despite the fact of having low hematological toxicity, the clinical use of 
anthramycin is restrained because of dose-limiting damage to the heart muscles.8  The undesired 
side effects of the naturally occurring PBDs have led to an increase in research on the synthesis 
of analogs. Two examples that have been tested in vivo against various human xenografts are 
SG2042 and SG2738 which have the C10-C11 imine structure, but no noticeable DNA damages 
have been identified yet. Also, the structure activity relationship (SAR) studies have shown that 
the correlation of the primary position C8 of DC-81 with the moieties of DNA intercalators or 
pyrrole and imidazole polyamide analogs of distamycin and neotropsin have produced PBD 
conjugates having pharmacophoric heads with enhanced in vitro DNA binding affinity and 
cytotoxic efficacy.9 An important discovery of PBD antitumor agents was the PBD dimers which 
were made to create cross-links in the DNA by forming the guanine bases at the end of each 
molecule. The assessment of antitumor activity of PBD is controlled by in vitro cytotoxicity 
against tumor cells lines and DNA foot printing assay. DNA thermal denaturing experiments are 
used to measure DNA- binding affinity and find the sequence selectivity of these compounds.10,11 
The general features of pyrrolo [2,1-c] [1,4] benzodiazepines in this research include an 
aromatic or non-aromatic pyrrole ring and two carbonyl group on the diazepine ring which is at 
position 5 and 11 on the PBD. These compounds are called “dilactams.” In the past five years, 
three novels [2,1-c] PBD synthesis have been reported in this division of compounds: (Section 
“Reductive cyclisation of N-(2-azidobenzoyl)pyrrolidine-2-carboxaldehydes”), (section 
“cyclisation of N-(2-azidobenzoyl)pyrrolidine-2-carboxaldehydes”) but new compounds [2,1-c] 




What is Cancer? 
After cardiovascular disease, cancer is the second major cause of death in the world. It 
has been estimated that about half of the men and one-third of the women are likely to develop 
cancer at a point in their life. 12 The human body contains millions of cells that are constantly 
growing and dividing in a regular plan, but these cells are likely to grow uncontrollably leading 
to cancer. Cancer cells have the propensity to proliferate and spread in every part of the human 
body. Not all tumorous cells spread relentlessly in the body, most are not malignant. Normal 
cells can control their growth and when they decline in their activity, they are able to destroy 
themselves. Lymphoma cancer can be detected when one is vulnerable to aldehydes and 
formaldehyde. Sometimes a solid growth of the tumor can occur which could be because of lack 
of oxygen in the tissues. Trying to single out a specific cause of cancer is difficult, but there may 
be risk factors which increase the chance of one getting cancer. Exposure to ultraviolet radiation 
and some lifestyles which include a poor diet, tobacco, alcohol and obesity are some of the 
contributing factors that can cause cancer. Additionally, lack of physical exercise contributes to 
about 5% of cancer cases. This can also be attributed to people inheriting damaged DNA. The 
latest research from at NCI reveals that people who are exposed to solvent, grease, and oils have 
a higher risk of getting cancer. If cancer is identified at its early stages, it could be treated, and 




History and Major Cancer Types 
From 460-370 BC, Hippocrates explained cancer which originates from the Greek word 
“Karkinos” as an abnormal mass of tissue. The oldest case of cancer recorded was breast cancer 
which happened in Egypt around 1500 BC. At that time there was no treatment.12,13 
Major Cancer Types 




Carcinomas. So far, 85% of carcinoma cases have been diagnosed and these develop in 
the epithelial cells. There are four sub-types which include: 
Adenocarcinoma (example Lung cancer) 
Squamous cell carcinomas (example oral cancer) 
Transitional cell carcinomas (example bladder cancer)  
Basal cell carcinomas (example skin cancer) 
Lung cancer. The main role of the lungs is breathing, and when we take in air, it spreads 
to the bronchi tubes. There are two types of lung cancer namely Non-small lung cancer and small 
cell lung cancer which can combine to form metastatic cancer.13  Some of the causes of lung 
cancer are attributed to cigarette smoking. Also, alcohol intake and tobacco use can cause lung 
cancer. People who are exposed to air pollution and high level of arsenic are susceptible to this 
25 
 
type of cancer. This type of cancer is mostly seen in the aged group and less common in people 
below 40 years.14 It is difficult for the symptoms to show at an early stage, however, others like 
chest pain, breathing problems and loss of weight becomes evident as cancer progresses.15 
Oral cancer. This is a type of squamous carcinoma cell cancer which is enclosed in the 
epithelial neoplasm of the oral cavity.16 Oral cancer can affect the gums and the floor of the 
mouth. Also, the salivary gland tumor is a part of oral cancer. Some of the causes of this cancer 
are attributed to lack of oral hygiene, smoking, and an intake of alcohol. Also, the use of 
immune-suppressant drugs during filling of the teeth can also cause this type of cancer. Some of 
the symptoms of this kind of cancer include mouth sores, mouth ulcers, difficulty in speaking, 
and some cracks in the edge of the mouth.13,17 
Bladder cancer. This is often located at the bladder areas occupying the central part of 
the lower belly. Potential causes of this type of cancer are frequent exposure to arsenic and those 
who also drive trucks. Some chemical agents can cause this type of cancer. Symptoms of this 
type of cancer include weight loss, fatigue, blood seen during urination, and abdominal pains.18,19 
Skin cancer. This is one of the most common cancers widely known. Each year this type 
of cancer is diagnosed in far more than 1 million people in the USA. There are two types of this 
cancer, namely non-melanoma and melanoma.20,21 The commonly seen ones are the 
nonmelanoma which is less dangerous than melanoma. Some of the causes of skin cancer are 
exposure to ultraviolet light exposure, high amount of X-ray, exposure to toxic chemicals like 
arsenic. Also, working in the mining and plastic industry raises the risk of getting this type of 
cancer. Common symptoms of this type of cancer include the skin becoming red and scales begin 
to appear. Itching and ulcers develop as well as bleeding and tanning.13,22 
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Lymphomas. This is the type of cancer in the lymph cells of the immune system. People 
who are diagnosed with lymphoma have their lymph nodes gradually develop lumps over a 
period.23 
Sarcomas. This is a type of cancer is found in the mesoderm tissue. Tumors are found in 
fat, bone, muscle, and hematopoietic tissue. Soft tissue sarcomas exist in the form of malignant 
fibrous histiocytoma.24,25 
This type of cancer can be found in patients that are treated with radiation therapy. Also, those 
who work at places using chemicals such as arsenic and phenoxyacetic acid are at risk of this 
type of this cancer. Chemicals in herbicides can also cause sarcomas.26 Major symptoms are 
found all over the body. It is accompanied by pain in nerves and muscles. Bleeding may occur in 
the tumor.27 
Sources of Cancer 
This is study looked at sources of cancer in two divisions: Chemical and Environmental 
sources. 
Chemical sources. Data from the NCI has concluded that 30% of cancer deaths is 
associated with smoking in the USA. Out of this, lung cancer contributes to 87% cases 
recorded.28 Avoiding smoking can tremendously reduce the risk of cancer. 
Exposure to asbestos, which contains silicon and oxygen molecular structures, is linked to this 
source of cancer. There are two major types of asbestos minerals, namely serpentine asbestos, 
and amphibole asbestos. Genetics is also a factor in cancer growth and cancer development. 
History of cancer in one’s family, such as breast cancer, means extra cautions must be taken. 
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Genetic cancer is likely to pass mutated genes onto the next generation. The fact that a person in 
someone’s family has cancer does not mean they will also automatically get it. However, there is 
a probability of them also developing cancer. Working out for about 30-40 minutes a day, can 
lower the chance of some cancers. From statistics, obesity is a major cause of cancer. Routine 
exercise can prevent colon, breast, lung, and prostate cancer.13,29 
Environmental Sources. The environment plays an important role in influencing some 
types of cancers. Skin cancer is attributed to exposure of ultraviolet rays of the sun. Tanning and 
skin burn are ways of damaging the cells. This can be prevented by using sunscreen when one is 
exposed to the sun’s intense rays. Also, having unprotected sex makes one vulnerable to Human 
Papilloma virus (HPV). HPV is an assortment of more than 100 viruses that can contribute to 
raising the chance of cancer associated with anal, vulvar, cervical, and vagina. More studies are 
being conducted on HPV’s function in the growth and development of other cancers.13,15,29 
 
Treatments of Cancer 
There are three types of cancer treatment which includes surgery, chemotherapy, and 
radiation therapy. Surgical treatment involves taking out tumors by removing lesions of the 
tumors. This process lessens the cancerous cells but cannot absolutely eliminate. It minimizes the 
cancer but may develop again. Alternative ways employed in eliminating cancer include, 
ultrasonography, open surgical and Biopsy exploration. 
Chemotherapy is the process of using anti-cancer drugs to kill cancerous cells.15,30 Using 
tamoxifen, skin cancer appears normal after treatment.31 Radiation therapy is the process of 
killing cancer cells using X-rays, gamma rays and charged particles. Some cancer cells can be 
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treated with the combination of all the three treatments. A good example is head and neck 
squamous cell cancer.32,33 
 
Anti-Cancer Activity of PBD-Derivatives 
Anti-cancer activity of compounds from literature 34 carried out in selected cancer cell 
including cervix, lung, colon, oral and ovarian using sulforhoda- mine B (SRB) method. The 
compounds showed GI50 ≤ 10
-5 M, implying that they were active on the cell lines tested. All the 
conjugates showed good anti-cancer activity. The good GI50 values ranging from less than 0.1 to 
2.81 µM while the positive control also showed a GI50 range of 0.10-7.25 µM. Every conjugate 
synthesized showed significant anticancer activity against hormone-dependent (estrogen receptor 
positive) MCF-7 cell line having GI50 values ranging from less 0.1 to 0.17 µM, C2-monofluoro-
PBD estradiol conjugates, gave a slightly better anticancer activity compared to the E2-PBD 
conjugates. It was discovered that the addition of the piperazine and triazole moieties in the 
alkane linker spacer between the estradiol and PBD subunits enhanced the anticancer activity. 
Also, PBD conjugates with propyloxy spacers showed a slightly more activity compared to the 
pentyloxy spacers.34 
Anti-cancer activities of PBD compounds synthesized from literature 35 showed cytotoxicity 
towards cancer cells. Single dose invitro studies on NCI-60 cancer cell lines at a concentration of 
10 µM performed at NCI showed that, (S,Z)-11-(propylimino)-1,2,3,10,11,11a-hexahydro-5H-
benzo[e]pyrrolo[1,2-a] [1,4]diazepin-5-one (18) and 3-phenyl-1-propyl-1,12,13,14,14a,14b-
hexahydro-2H,10H-benzo[e]pyrimido[2,1- c] pyrrolo[1,2-a][1,4]diazepine-2,4,10(3H)-trione(19) 
had inhibition on cell lines SNB-75 (CNS) (22.3%) and NCI-H522 (NSCL) (22.2%), 
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respectively. Maximum inhibition activity was exhibited by compound (S)-3-phenyl-
1,12,13,14,14a,14b-hexahydro-2H,10H-benzo[e]pyrimido[2,1-c] pyrrolo[1,2-a] [1,4] diazepine-
2,4,10(3H)-trione (20) on the renal UO-31 cell line with a 28.5% growth inhibition. (S)-
11,12,13,13a-tetrahydro-9H-benzo[e]pyrrolo[1,2-a] [1,2,4] triazolo[3,4-c] [1,4] diazepine-
3,9(2H)-dione (21) showed growth inhibition in both the HOP-62 and NCI-H522 cell lines at 





































History of Antibiotics 
Since the discovery of penicillin by Fleming in 1928, β-lactam antibiotics have been 
widely used for the treatment of bacterial infection. A lot of β-lactam drugs which are still used 
today came from natural product organisms like penicillin, cephalosporin, and other β-lactam 
based antibiotics. 36 Over time, bacteria have developed resistance to the β-lactams because the 
drugs produced had the same mode of action which was inhibition of the bacterial cell wall 
formation by forming a stable covalent bond with the active site of serine residue of penicillin-
binding proteins. High molecular weight penicillin-binding proteins and low molecular weight 
penicillin-binding proteins are the two classes of penicillin-binding proteins. The β-lactams were 
targeted at the high molecular weight penicillin-binding proteins, which was very essential for 
bacteria existence. 37 The clinical use of β-lactam antibiotics in the present age (Figure 3) include 
cefotaxime, monobactams e.g. aztreonam, and carbapenems. Classes of antibiotics have a similar 
structural character, that is the four-membered β-lactam ring which is reactive. Microorganisms 






























































































Figure 3: Examples of the first generation of β-lactam antibiotics 39 
 
Mechanism of β-lactam Resistance 
β-lactamase breaks a bond in the β-lactam ring of the penicillin to render the molecule 
ineffective. Bacteria with the enzyme β-lactamase may be able to resist the effect of penicillin 
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and other β-lactam antibiotics. The penicilloic acid form will not be able to deactivate the cell 
wall of the bacteria. The resistance of bacteria to β-lactams and other antibacterial agents is a 
serious concern and there is a need to research and look for new and effective ways to address 
this problem. Bacteria have a lot of resistant-mechanisms against β-lactam antibiotics in many 
forms.4,40 The most widely used mechanism of resistance in gram-negative bacteria is the 
production of β-lactamases that cleave β-lactam ring by means of hydrolysis. Rapid resistance 
over a broad range of bacteria is possible by the transfer of plasmid-encoded β-lactamases.41 One 
vital mechanism employed by gram-positive bacteria (e.g. methicillin-resistant S. aureus 
(MRSA)) for its resistance is the formation of low-affinity PBPs that are involved in breaking 
down the transpeptidase reaction. The main factor that enhances the resistance of 
microorganisms to β-lactam antibiotics is due to mutation. Because of that, PBPs has low-
affinity to β-lactams. Typically, PBPs of class B (homologous to Escherichia coli PBP3) are 
mostly affected by this mechanism because they are primary targets of β-lactam in these 
microorganisms.42 Some microorganisms such as S. pneumoniae PBP2X, Neisseria gonorrhoeae 
PBP2 have been found to contain mutations.43 Also, resistance to β-lactams can occur by gene 
transfer which can be horizontal, for example, the resistance in Streptococci is by the 
transformation which is considered natural.44  
Movement of β-lactams through the outer membrane is enabled by Outer membrane 
proteins (OMPs). When the rate of OMPs declines, a decrease in the concentration of antibiotics 
at the periplasm is detected and an increase in MIC-values.45,46 In gram-negative bacteria, efflux 
pumps can reduce the effective concentration of β-lactam antibiotics in the periplasm. β-lactams 
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is then transported outside the cells by the outer membrane by the outward flow pumps in 
bacteria.46 
The alarming rate of β-lactam resistance has urged the advancement of a lot of strategies 
to fight this issue. The abuse of antibiotics is the main factor contributing to the increase in this 
trend. The drive of pharmaceutical industries to continue research in quest of antibiotic resistance 
has reduced drastically in the last 23 years. Inactivators and “suicide inhibitors” of class-A β-
lactamases have been used for some time now. These β-lactamases inhibitors are clavulanic acid, 
tazobactam, and sulbactam (Figure 4), they are great reactive four-membered β-lactam ring. 
When the β-lactamase inhibitors are used in combination with β-lactam antibiotics such as 
amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin/tazobactam, they significantly lower 
the MICs of the β-lactam antibiotics against varieties of bacteria. As these combination drugs are 
used over a period, they encounter resistance from the proliferation of inhibitor of β-lactamases. 
The drawbacks of these molecules are that they are hydrolyzed by β-lactamases. Hence, their 
performance is increased when combined with a β-lactamase inhibitor. Non-β-lactam inhibitors 
of PBPs have shown to be preferred substitute for the resistance of β-lactamase than β-lactam 
due to their distinctive properties. This makes it impossible for β-lactamases to identify them as 
substrates. Researchers have worked hard in the last three decades to find non-β-lactam 
inhibitors that can substitute β-lactams. NXL104 has been the only non-β-lactam β-lactamase 
inhibitor that has been studied in clinical trials to date.7,40,47 The examples below show when the 
parent structure of traditional β-lactam has converted to new molecules which have important 
activities against resistant pathogens that are of medicinal value. Significant activity on PBP2a of 
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a methicillin-resistant S. aureus has been observed by the action of non-traditional β-lactams 























































































β-lactamase enzyme was first isolated from Bacillus Escherichia coli and described as B. 
coli “penicillinase”. 54 As at that time β-lactamase was not of clinical significance because 
penicillin was only used to treat staphylococcal and streptococcal infections. Scientists were 
unsuccessful to separate the β-lactamase enzyme from Gram-positive organisms. 54–56 Successful 
isolation of β-lactamase was done by Kirby et al. from Staphylococcus aureus and he observed 
that it could be a possible major clinical problem as these enzymes are likely to be the major 
causes of resistance in bacteria throughout the world. 57  
More than 850 β-lactamases have been identified and it has also been considered that 
active recombination, high mutation frequency, and replication rates have been the bedrock for 
bacteria to adjust to new β-lactams by the production of these β-lactamases.58 
 
Classification of β-lactamase 
  β-lactamase enzymes are classified into two main groups these include: 
1. Classes A to D, using Amber classification focusing on the sequence of amino acid homology, 
and 
2. Group 1 to 4 using Bush-Jacoby-Medeiros classification focusing on substrate and inhibitor 
scheme.58,59 
Classes A, C, and D serine-β-lactamase have some equivalence in their structure which gives 
them the ability to cleave β-lactams by hydrolysis. However, class B β-lactamases are metallo-β-
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lactamases (MBLs) and they have a Zn2+ ion linked to His/Cys/Asp residues in the active 
site.60,61 
 The type classification structure used in this literature review is Amber. 
-lactamases
Serine -lactamases Metallo -lactamases
Class B
cCRA IndB




Figure 5: Classes of β-lactamases 
 
Class A Serine β-lactamase. A lot of class A enzymes are easy target to β-lactamase 
inhibitors that are accessible on the market which includes clavulanate, But K. pneumoniae 
carbapenemase (KPC) is exempted to this category as they are unaffected to clavulanate.62 
Class A Extended-spectrum β-lactamases (ESBLs). They can chemically breakdown by 
hydrolysis of the oxyimino-cephalosporins, monobactam, and carbapenems. This category of 
lactamase activity can be restricted by clavulanate.63 
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Class A Serine carbapenemases β-lactamases. This class comprises of non-metallo 
carbapenemase of class A (NMC-A), IMI, SME, and KPC. They can cleave the first generation 
β-lactams by hydrolysis examples of such include carbapenems, penicillin, and aztreonam 
cephalosporins. This category of β-lactamases have been studied and noticed to be predominant 
in K. pneumoniae, Serratia marcescens, and Enterobacter cloacae, but they are an easy target to 
clavulanate 64 
Class B Metallo-β-lactamases. This class of β-lactamases relies on Zn+2 and they cleave 
β-lactam antibiotics by hydrolysis. But the mechanism used is not similar compared to the of rest 
other β-lactamases. They can cleave β-lactams using hydrolysis and are also able to withstand 
activities from penicillin, cephalosporins and carbapenems,.56,65 
Class C Serine cephalosporinases. Serine cephalosporinases of class C contain the bla 
genes of the bacterial chromosomes. Organisms that have this β-lactamase are can mostly 
withstand the action of penicillin, β-lactam β-lactamase inhibitor combinations, and 
cephalosporins. But AmpC enzymes, as an example of this category of serine β-lactamases, are 
known to be restricted by their mode of action with aztreonam, oxacillin, and cloxacillin.60,65 
Class D Serine Oxacillinases. Initially, they were referred as “oxacillinases” because they 
can breakdown oxacillin at a faster rate of 50% compared the slow pace cleavage of oxacillin by 





Non-β-lactam Lactamase Inhibitors 
Non-β-lactam based PBP inhibitors have been found to withstand β-lactamase hydrolysis 
which has caught the attention of many and more emphasis has been put on the exploration of 
non-β-lactam derivatives. NXL104 (avibactam) (Figure 4) is a non-β-lactam that can prevent the 
activity of serine β-lactamases. When avibactam is used together with broad-spectrum 
cephalosporins and aztreonam, it is active against Gram-negative infections (including 
Klebsiella). Avibactam is the maiden β-lactamase inhibitor to undergo clinical trials.67–69 
 
Classification of non β-lactam based PBP inhibitors are identified in three groups: 
1. Transition state analogs 
2. Substrate analogs and 
3. Non-covalent inhibitors 
1. Transition State Analog. These inhibitors have been recognized to be useful protease 
inhibitors and serine β-lactamases.70–72 Transition state analog inhibitors like boronic acid, 
carbonyl compounds, and phosphonates have been classified as effective inhibitors of PBPs. 
LMW-PBPs have binding affinity to boronic acid.36,73  Reversible and covalent bonds with serine 
proteases have been associated with boronic compounds which prevent these enzymes by 
adopting tetrahedral intermediates of the reaction.74,75 Phosphonates are good inhibitors of serine 
proteases which have their clinical ability narrowed because of they are unable to stay longer in 
aqueous solution and affected by phosphodiesterases.70,76 
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2. Substrate Analogs. Acylation of the effective serine PBP makes them act as suicide 
substrates. Also,81 lactivicins (LTV) and Bicyclic pyrazolidinones and they have demonstrated 
some clinical significance related to PBP inhibitors and antibacterial activities.77–79 
 3. Non-covalent Inhibitors. They bind firmly to the active site of PBPs using other means 
apart from acylation, which makes them very potent inhibitors. They do not need the undesirable 
changes in the active site of PBP2a of MRSA that is needed for acylation.80,81 Examples of non-
covalent inhibitors are  aminothiadiazole, inhibitors of class C β-lactamases, and ortho-
phenoxyldiphenylurea derivatives, anthranilic acids, naphthalene sulfonamides, cyclic peptides, 
Cibacron Blue and Erie Yellow, and quinolones. Inhibitors of PBPs that are classified as 
Noncovalent of E. coli and B. subtilis have been discovered on 4-Quinolones .82–88 
 
The Endocannabinoid System 
 The endocannabinoid system is comprised of endogenous cannabinoids 
(endocannabinoids), cannabinoid receptors and the synthetic and degrading enzymes involved in 
the synthesis and the breakdown of endocannabinoids.89–91 They are called endocannabinoids 
because they were first recognized to activate the same receptors as cannabinoids, which is the 
principal psychoactive ingredient of cannabis. Endocannabinoid that was identified first was 
arachidonoyl ethanolamide. 2-arachidonoyl glycerol (2-AG) was the second endocannabinoid 
identified. Synthesis, cellular transport and breaking down of endocannabinoids are processes 
that are strictly regulated.90,92 Endocannabinoids differ from other neuromodulators in that they 
are not produced in advance and stored in vesicles but rather, their precursors remain in cell 
membranes and are cleaved by specialized enzymes. This can also be termed as they are 
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produced when there is a need for them.93–95 The psychoactive properties of ∆9-
tetrahydrocannabinol (THC), which is the main psychoactive ingredient of cannabis became a 
point of interest with the identification of cannabinoid receptors. A lot of various experiments 
suggested the probable existence of specific protein receptors for ∆9-THC, but Howlett et al.90 
gave definitive confirmation for a cannabinoid receptor. The outcome of their work was that 
cannabinoids activated a G protein-coupled receptor (GPCR) inhibited adenylyl cyclase. They 
also developed an assay for receptor binding activity and found out that this receptor was present 
in some brain regions at high levels. GPCRs that are expressed in greater quantity includes 
cannabinoid receptor cannabinoid receptors. Initial autoradiographic studies showed that 





Figure 6: Structure of ∆9-tetrahydrocannabinol (THC) 
The mammalian tissue has two types of cannabinoid receptors. They are CB1 receptors, which 
was cloned in 1990,98 and CB2 receptors, cloned in 1993.
99 Anandamide acts as a partial 
cannabinoid agonist receptor with higher CB1 than CB2 affinity.
100 Anandamide and 2-
arachidonoyl glycerol may both serve as neurotransmitters or neuromodulators. 
Endocannabinoids uses the reverse synapse for signal transduction. 101 Expression of CB1 
receptors are seen in the central nervous system and in some peripheral tissues. Examples 
include but not limited to the heart, kidney and the lungs. CB2 receptors are found principally in 
the immune cells, especially B-cells and natural killer cells.102 CB1 receptors can also found on 
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pain pathways in the brain and spinal cord and they are also likely to be found at the peripheral 
ends of primary afferent neurons.103 
Signaling of Cannabinoid Receptors and Modulation Release of Chemical Messengers 
   CB1 and CB2 receptors primarily send signals through the inhibitory G proteins Gi and Go. 
When the inhibitory G protein activation is triggered by CB1 receptors adenylyl cyclase is 
inhibited. This causes mitogen-activated protein kinases to be activated, leading to the shutting 
down of some voltage-gated calcium channels and finally activating of G protein-linked within 
adjusting potassium channels. CB2 receptors have almost the same effects when stimulated, 
except that the regulation of ion channels by CB2 receptors is more fluctuating. Suppression of 
neuronal excitation by CB1 receptors prevents neurotransmission. Considerable evidence clearly 
shows that endocannabinoids perform an important role in several forms of brain plasticity. 
There are two types of plasticity; namely short-term and long-term. 89,90,104 Endocannabinoids are 
produced in a short time but their effects last longer. More studies analyzing the effects of 
endocannabinoid have much emphasis on neurotransmission however, there is proof of functions 
associated with somatic CB1 receptors, which when activated hyperpolarizes neurons.
105,106 
 The main property of CB1 and CB2 is to be able to control the release of chemical 
messengers by natural or induced means. Neurotransmitters are release from both central and 
peripheral neurons are inhibited by the presynaptic CB1 receptors and cytokine released are also 
hindered or facilitated when CB2 receptors on immune cells are activated. Currently, 
cannabinoid-receptor regulated effects on cytokine release have recently been explained. When 
CB1 receptors are activated during pre-synapse, it leads to inhibition of chemical messengers 
from some areas of the brain and peripheral neurons. In vivo or in vitro activity have been 
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conducted on some compounds like dopamine, acetylcholine, and D-aspartate and the outcome 
has confirmed the release of neurotransmitters.   
   Some research findings also shows that when CB1 receptor is activated: (a) They can 
increase the natural firing of neurons in the pars reticulata of rat substantia nigra and does not 
affect the effects of neurons to iontophoretically applied GABA (b) can limit the occurrence but 
not the amplitude of miniature IPSCs that were assumed to be stimulated by natural neuronal 
release of single GABAergic synaptic vesicles (c) has no substantial decline in effect on neuronal 
firing rates or inside currents stimulated by internal dispensation of GABA.107,108 
 
Justification of Research 
The interaction between PBD and DNA is studied using the DNA helical structure. The 
double-helical DNA structure contains two parts: major and minor grooves. The major groove is 
wide in space compared to the minor groove which makes it possible for molecules like protein 
to interact with it. Molecules that are small and usually less than 1000 Da can bind to the minor 
groove. The difference in the size of the grooves is because the sugar-phosphate backbone is not 
evenly spaced. Major and minor grooves have a specific arrangement pattern in which each base 
have hydrogen bond donors and acceptors. Selective drug uses the size, spacing and the 





Figure 7: Hydrogen bonding between adenosine/thymine (left) and guanosine/cytosine (right) 
base pairs of DNAs.109 
 
The configuration of PBD at carbon C-11a gives the molecule a right-handed twist. The right-
handed twist fits well to the B-form of the DNA giving it the ability to interfere with the 
processing of the DNA forming adduct in the minor groove. Synthetic PBD with R-configuration 
has no DNA binding activity and in vitro cytotoxicity. The minor groove is mostly unoccupied 
and likely to be exposed for small molecules to be attacked. PBD have electrophilic carbon at C-
11 position and this with the right-handed twist of the molecule allows PBD to alkylate the 
nucleophilic NH2 group of the guanine in the minor groove of the DNA. PBD can form covalent 
bonds guanine base of the DNA to obstruct the activity of biological processes. The structure-
activity relationship (SAR) on cytotoxicity and anti-tumor activities of PBD has not been fully 
understood.110 
The main goal for further advances in research of PBDs as potential non-β-lactam lactamase 
inhibitors was because the active regions of characteristic β-lactam β-lactamase inhibitors are 
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tantamount to the PBD core structure whiles maintaining the same active sites of a regular non-
β-lactam β-lactamase inhibitor. (Scheme 1). PBDs can act as suicide inhibitors against Serine β-
lactamase. Clavulanic acid, which is one of the first β-lactam β-lactamase inhibitors, is a suicide 
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Exploring the cannabinoid receptor with PBD is to enable us to understand the structure-activity 
relationship of receptor binding sites. Understanding the SAR of cannabinoid binding receptor 
will help in finding new substances of therapeutic effect. The principal active ingredients in 
Cannabis sativa which is Tetrahydrocannabinol (THC) has some structural similarities to PBD 
derivatives. 
 Alkyl groups with a short chain on THC lowers the efficacy to bind to the cannabinoid 
receptor. Also, when the number of carbon atoms are increased, the potency of the ligand to bind 
to the cannabinoid receptor is increased. Compounds with ring-opening that includes pyran only 
shows small extent of affinity towards CB1/CB2 cannabinoid receptors. 
 THC analogs without phenolic hydroxyl groups may show some substantial changes in 
their pharmacological abilities. It was noted that THC derivatives that experienced etherification 
or elimination of the phenol group exhibited good affinity for CB2.
111 
 THC have 19 carbons in its structure with a molecular weight of 314.5g/mol, in this 
research, PBD derivatives have 19-23 carbons in their structure and with a molecular weight of 
318g/mol to 403 g/mol. Structural modifications of PBD derivatives in this research has been 
enhanced to determine a potential cannabinoid receptor binding activity. 
 
Specific Aims 
 Novel synthesis and structure-activity relationship (SAR) of lead compounds were 
fundamental to this research. Enzyme kinetic inhibition was conducted on the PBD derivatives 
using lactamases TEM-1, P99 and AmpC to determine the percentage of inhibition. To 
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determine the compounds synthesizes as potential anti-cancer agents, NCI determined the 
percentage of inhibition of the PBD derivatives on 60 cancer cell lines. Other Biological activity 
of the PBD derivatives including preliminary cannabinoid binding activity was conducted on one 

















CHAPTER  2 
RESULTS AND DISCUSSION 
Synthesis of Pyrrolo[2,1-c] [1,4] Benzodiazepine (PBD) Derivatives 
Novel derivatives of PBD Synthesis was done using starting material from the primary structure 













































Scheme 3: Reagents and conditions of compound 4(a-f)  (a) DMF, 155 ºC, 5 h; (b) Lawesson’s 
reagent, THF, rt, 15 h; (c) N2H4.H2O (98%), EtOH(abs.), rt, 15 h; (d) Aldehydes, MeOH 










































Scheme 4: Reagents and conditions of compound 8 (a) DMAP, DCM, Boc2O, rt, 15 h; (b) 
MeOH (anhyd.), rt, 15 h. (c) K2CO3, MeOH/H2O, reflux 30 min. 
 
(S,E)-11-hydrazono-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-a] [1,4] diazepin-5-one 
(3) 
Synthesis of compound 1 was done using procedures literature112–114cyclocondensation of 
equimolar of isatoic anhydride with (L)-proline in DMF for 5 hours. Recrystallization from 
acetone/DMF (v/v 10:1) gave 82% yield, 1H NMR in DMSO-d6 displayed 12 signals; a singlet 
for the N-H group at 10.51 ppm, two each of doublet-doublet and doublet-doublet-doublet for the 
aromatic protons between 7.79-7.11 ppm, a doublet for the 11aH between 4.10-4.12 ppm, and six 
multiplets for the three CH2 groups on the pyrrolidine ring between 1.78-3.59 ppm (refer to 
spectra in Appendix A1, A2 and A3) three signals were predicted but more splitting of the 
49 
 
individual multiplets gave  a total of six multiplets from the pyrrolidine ring.  The individual 
peaks were integrated to give relatively 1:1:1:1 ratio for the aromatic protons and 1 for the 11aH 
doublet peak. 13C NMR also produced 12 peaks. Secondary and tertiary amide carbons were 
observed at 171.315 and 165.090 ppm C=O respectively. Six of the aromatic carbons were found 
between 121.832-136.957 ppm and the C11a which is the stereocenter gave a peak at 56.772 
ppm. The following peaks 47.435, 26.338, 23.638 ppm were three CH2 groups on the pyrrolidine 
ring (refer to spectrum in Appendix A4). 13C-DEPT 135 analysis validated the number of 
methylene CH and methine C-H groups in the structure. The spectrum showed 3 negative signals 
in the negative phase for the three CH2 groups on the pyrrolidine ring and 5 signals for the 
methane groups all in the positive phase; 4 aromatic C-H groups and a C11a signal.  But, 
quaternary carbons were not seen in the spectrum (refer to spectrum in Appendix 5). Gas 
Chromatographic Mass Spectrometry analysis of 1 in chloroform showed molecular ion peak at 
m/z = 216.0 amu and a base peak at m/z = 70.0 amu. IR analysis gave peaks at 3218 cm-1, 2975 
cm-1 and 1619 cm-1 for the secondary amide, C-H and the C=O stretching sequentially (refer to 
spectrum in Appendix A7).  
Monothionation of compound 1 with 2,4-bis-(4-methyoxyphenyl)-1,3-dithia-2,4-
diphosphetane-2,4-disulfide (Lawesson’s reagent) in THF at room temperature for 28 hours112–
114 produced compound 2 a yellow solid in good yield (Scheme 3). 1H NMR, 13C NMR and 13C-
DEPT 135 spectra in DMSO-d6 gave signals identical to compound 1 except that the 13C NMR 
spectrum gave distinctive peaks at 202.568 ppm for C=S and 164.746 for ppm C=O of the 
tertiary amide that was not the same as compound 1 (refer to spectra in Appendix B1, B2, and 
B3). IR analysis gave stretching peaks at 3450 cm-1, 2969 cm-1 and 1619 cm-1 for the N-H, C-H 
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and the C=O for amide respectively (refer to spectrum in Appendix B7). GC/MS analysis of 
compound 2 in chloroform produced molecular ion peak at m/z = 232.0 amu and a base peak at 
m/z = 70.0 amu.  
Synthesis of compound 3 was done using procedures from literature115 by stirring a 
mixture of compound 2 and hydrazine monohydrate (98%) in absolute ethanol at room 
temperature for 15 hours. Evaporation of the solvent was done in a vacuum and the residue was 
taken up in water. The precipitate was dried and washed with diethyl ether to afford compound 3 
as an off-white solid. Compound 3 was then used as starting material for the synthesis of novel 
compounds from 4a to 4g in good yields (Scheme 3). 1H NMR of compound 3 in CDCl3 gave 
two doublet and two triplet and peaks for the aromatic protons between 6.82-7.86 ppm. A singlet 
peak for the N-H group at 7.29 ppm, another singlet for the 11aH at 4.22 ppm and six multiplets 
for the three CH2 groups on the pyrrolidine ring between 1.93-3.70 ppm (refer to spectra at 
Appendix C1 and C3). 13C NMR gave 12 proposed peaks with the peculiar peaks at 166.207 
ppm for C=O and 152.152 ppm for C-N ppm. The 6 aromatic carbon peaks were found between 
119.744-137.768 ppm and the C11a peak showed at 55.495 ppm. The three CH2 groups on the 
pyrrolidine ring also produced peaks at 23.401, 26.093 and 47.328 ppm (refer to spectrum at 
Appendix C4). IR analysis showed peaks at 3261 cm-1, 2871-2948 cm-1 and 1631 cm-1 for the 




General method for synthesis of (S, E)-11-[2-(arylmethylene) hydrazono] Pyrrolo [2,1-c] [1,4] 
Benzodiazepine (4a-f) 
Synthesis of compounds (4a-g) was done by reacting compound (3) in anhydrous 
methanol using modification of procedures 116 with different aldehyde and stirred at room 
temperature.  
 





























The general procedure was followed, and benzaldehyde used for the reaction. Extraction 
was done with chloroform/isopropanol after the reaction was completed. The organic layer was 
dried over anhydrous sodium sulfate and the solvent was then removed in vacuum, washed with 
diethyl ether to afford an off-white solid of compound 4a. The final product was purified from 
isopropanol to yield colorless needle shape crystals. 1H NMR of 4a in CDCl3 gave two doublet, 
two singlet and one triplet peak for the aromatic protons between 6.98-7.97 ppm. A doublet peak 
for N-H, N=C-H group between 8.53-8.48 ppm. A doublet for the 11aH between 4.37-4.38 ppm 
and a double doublet for N-CH2 between 3.65-3.83 ppm on the pyrrolidine ring. A singlet and a 
multiplet were recorded for the two CH2 groups on the pyrrolidine ring between 2.02-3.02 ppm 
(refer to spectra in Appendix D1, D2, and D3). 13C NMR gave 17 proposed peaks with the 
peculiar peaks at 166.06 ppm for C=O, 157.82 ppm and 157.62 ppm for the two C=N ppm. 
Instead of 12 aromatic carbon peaks, 10 carbon peaks were found between 120.77-136.80 ppm 
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because two of them were symmetric carbons. And the C11a peak showed at 55.52 ppm. The 
three CH2 groups on the pyrrolidine ring also produced peaks at 47.42, 26.15 and 23.56 ppm 
(refer to spectrum in Appendix D4 and D5). In 13C DEPT-135 all quaternary carbons 
disappeared and N=CH appeared on the positive phase at 157.83 ppm. 7 aromatic carbons were 
found on the positive phase between 120.77-132.47 ppm and C-11a showed on the positive 
phase at 55.52 ppm. All the CH2 on the pyrrolidine ring 47.39, 26.16 and 23.43 ppm appeared on 
the negative phase (refer to spectrum in Appendix D6). IR analysis showed peaks at 3351 cm-1, 
2981 and 2879 cm-1, and 1627 cm-1 for the N-H, C-H and the C=O stretching respectively (refer 
to spectrum at Appendix D7). UV-Vis absorption of the compound in methanol was at 223 and 
319 nm (refer to spectrum at Appendix D8). GC/MS analysis of the compound in acetone 
produced molecular ion peak at m/z = 318.0 amu and a base peak at m/z = 241.0 amu (refer to 


































Scheme 5: Proposed mechanism for compound 4a 
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The general procedure was followed, and 4-methoxybenzaldehyde was used and the 
reaction was stirred for 6 hours. The solution was filtered and washed with diethyl ether to afford 
a light-yellow solid of compound 4b. The final product was purified using crystallization from 
isopropanol to yield colorless needle shape crystals. 1H NMR of 4b in CDCl3 gave two doublet, 
two triplet and a multiplet peak for the aromatic protons between 6.92-7.96 ppm. A two-singlet 
peak for N-H and N=C-H group at 8.52-8.42 ppm respectively. A doublet for the 11aH between 
4.36-4.38 ppm and a multiplet for N-CH2 and CH3 between 3.69-4.38 ppm on the pyrrolidine 
ring. A two multiplet was recorded for the two CH2 groups on the pyrrolidine ring between 1.88-
3.01 ppm (refer to spectra at Appendix E1, E2, and E3). 13C NMR gave 17 proposed peaks with 
peaks at 166.11 for C=O, 161.83 C-O, 157.38 and 156.98 ppm for the two C=N ppm. 9 carbon 
peaks were found between 114.29-136.97 ppm. And the C-11a and CH3 peak showed at 55.50 
ppm. The three CH2 groups on the pyrrolidine ring also produced peaks at 47.40, 26.14 and 
23.55 ppm (refer to spectrum at Appendix E4). In 13C DEPT-135 all quaternary carbons 
disappeared and N=CH appeared on the positive phase at 157.21 ppm. 6 aromatic carbons were 
found on the positive phase between 114.28-132.47 ppm and C-11a and CH3 showed on the 
positive phase at 55.49 ppm. All the CH2 on the pyrrolidine ring 47.31, 26.10 and 23.57 ppm 
appeared on the negative phase (refer to spectrum at Appendix E5). IR analysis showed peaks at 
3259 cm-1, 2956 and 2854 cm-1, and 1627 cm-1 for the N-H, C-H and the C=O stretching 
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respectively (refer to spectrum at Appendix E6). UV-Vis absorption of the compound in 
methanol was at 221 nm and 325 nm (refer to spectrum at Appendix E7). GC/MS analysis of the 
compound in acetone produced molecular ion peak at m/z = 348.0 amu and a base peak at m/z = 
241.0 amu (refer to spectrum at Appendix E8).  
 
Figure 8: Spongy crystals of compound 4b from isopropanol 
 









The general procedure was followed, and 4-flurobenzaldehyde was used and the reaction 
was stirred for 4 hours followed by quenching with distilled water and filtered to give a white 
solid of compound 4c. The final product was purified using crystallization from hexane/acetone 
to yield white cube shape crystals. 1H NMR of 4c in CDCl3 gave two double, two triplet and 
peak for the aromatic protons between 6.98-7.97 ppm. A doublet peak for N-H and N=C-H were 
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found between 8.48-8.45 ppm. A doublet for the 11aH between 4.37- 4.39 ppm and a multiplet 
for N-CH2 between 3.67-3.81 ppm on the pyrrolidine ring. A two multiplet was recorded for the 
two CH2 groups on the pyrrolidine ring between 2.00-3.01 ppm (refer to spectra in Appendix 
F1, F2, and F3). 13C NMR gave 16 proposed peaks with peaks at 166.03 for C=O, 157.65 and 
156.52 ppm for the two C=N ppm. 9 carbon peaks were found between 115.94-136.74 ppm. And 
the C-11a peak showed at 55.50 ppm. The three CH2 groups on the pyrrolidine ring also 
produced peaks at 47.42, 26.14 and 23.55 ppm (refer to spectrum in Appendix F4 and F5). In 
13C DEPT-135 all quaternary carbons disappeared and N=CH appeared on the positive phase at 
156.52ppm. 7 aromatic carbons were found on the positive phase between 115.94-132.50 ppm 
and C-11a and CH3 peaks showed on the positive phase at 55.50 ppm. All the CH2 on the 
pyrrolidine ring 47.42, 26.19 and 23.55 ppm appeared on the negative phase (refer to spectrum in 
Appendix F6). IR analysis showed peaks at 3261 cm-1, 2950 and 2877 cm-1, and 1627 cm-1 for 
the (N-H), (C-H) and the C=O stretching respectively (refer to spectrum in Appendix F7). UV-
Vis absorption of the compound in methanol was at 222 nm, 236 nm and 313 nm (refer to 
spectrum in Appendix F8). GC/MS analysis of the compound in acetone produced molecular ion 






Figure 9: X-ray diffraction ORTEP analysis of compound 4c 
 
 
Figure 10: Crystals of compound 4c from hexane/acetone 
 
(S,E)-11-[2-4-(4-Formylphenyl) Morpholine Methylene Hydrazono] Pyrrolo [2,1-c] [1,4] 












The general procedure was followed, and 4-(4-formylphenyl) morpholine was used and 
the reaction was stirred overnight under nitrogen gas. Flash column chromatography using 
hexane/acetone (v/v 1:1) was used and the solvent was evaporated in vacuum. Crystallization of 
the compound was done using pentane to afford a yellow rod shape crystal of compound 4d. 1H 
NMR of 4d in CDCl3 gave four doublet and, two triplet peaks representing for the aromatic 8 
protons between 6.98-7.97 ppm. A two-singlet peak for N-H and N=C-H group at 8.40-8.52 ppm 
respectively. A doublet for the 11aH between 4.37-4.38 ppm and a multiplet for N-CH2 and O-
CH2 between 3.68-3.86 ppm on the pyrrolidine and morpholine ring came together respectively 
representing 6 protons. A singlet was observed for N-CH2 on the morpholine representing 4 
protons. A singlet and a multiplet were observed for the two CH2 groups on the pyrrolidine ring 
between 1.99-3.01 ppm (refer to spectra in Appendix G1, G2, and G3). 13C NMR gave 19 
expected peaks with peaks at 166.14 ppm for C=O, 157.59 ppm and 156.65 ppm for the two 
C=N ppm. 152.65 was observed for C-N which connects the phenylene and the morpholine ring. 
9 carbon peaks were found between 114.68-137.04 ppm. C-O on the morpholine peak was 
observed at 66.79 ppm while the C-11a peak showed at 55.50 ppm. C-N on the morpholine was 
observed at 48.22 ppm while the three CH2 groups on the pyrrolidine ring also produced peaks at 
47.40 ppm, 26.14 ppm, and 23.55 ppm (refer to spectrum in Appendix G4 and G5). In 13C 
DEPT-135 all quaternary carbons disappeared and N=CH appeared on the positive phase at 
157.59 ppm. 6 aromatic carbons were found on the positive phase between 114.67-132.44 ppm. 
CH2-O on the morpholine ring appeared on the negative phase at 66.8 ppm and C-11a and peak 
showed on the positive phase at 55.50 ppm. CH2-N on the morpholine ring appeared on the 
negative phase. All the CH2 on the pyrrolidine ring 47.40 ppm, 26.14ppm and 23.56 ppm 
appeared on the negative phase (refer to spectrum in Appendix G6). IR analysis showed peaks at 
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3259 cm-1, 2955 cm-1 and 2854 cm-1, and 1619 cm-1 for the N-H, C-H and the C=O stretching 
respectively (refer to spectrum at Appendix G7). UV-Vis absorption of the compound in 
methanol was at 235 nm and 350 nm. GC/MS analysis of the compound in acetone produced 




Figure 11: Crystals of compound 4d from pentane 
 








The general procedure was followed, and 4-ethylbenzaldehyde was used and stirred 
overnight under nitrogen and evaporation of the solvent was done in a vacuum. Crystallization of 
the compound was done using pentane to give a yellow solid rod shape crystal of compound 4e. 
1H NMR of 4e in CDCl3 gave a double doublet, two doublet and three triplet peaks for the 
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aromatic protons between 6.98-7.98 ppm. A doublet peak for the N-H, N=C-H group between 
8.53-8.48 ppm. A doublet for the 11aH between 4.37-4.38 ppm and a multiplet for N-CH2 
between 3.64-3.84 ppm on the pyrrolidine ring. A multiplet was recorded for one proton on the 
pyrrolidine ring between 2.98-2.99 ppm. A quartet was recorded for CH2 between 2.66-2.72 ppm 
and a multiplet was recorded for the CH2 groups on the pyrrolidine ring between 1.99-2.15 ppm. 
CH3 was between 1.24-1.27 ppm. (refer to spectra in Appendix H1, H2, and H3). 
13C NMR 
gave 19 expected peaks with the characteristic peaks at 166.11ppm for C=O, 157.86 ppm and 
157.31 ppm for the two C=N ppm. Instead of 12 aromatic carbon peaks, 10 carbon peaks were 
found between 120.76 ppm-147.59 ppm respectively because two of them were symmetric 
carbons. And the C11a peak showed at 55.53 ppm. The three CH2 groups on the pyrrolidine ring 
also produced peaks at 47.43 ppm, 26.15 ppm and 23.56 ppm whiles CH2 and CH3 of ethene 
attached to the phenyl was observed at 29.03 ppm and 15.50 ppm respectively (refer to spectrum 
at Appendix H4 and H5). In DEPT-135 all quaternary carbons disappeared and N=CH appeared 
on the positive phase at 157.86ppm. 6 aromatic carbons were found on the positive phase 
between 120.77 ppm-132.49 ppm and C-11a showed on the positive phase at 55.53 ppm. All the 
CH2 on the pyrrolidine ring 47.44 ppm, 29.04 ppm, 26.16 ppm, and 23.57 ppm appeared on the 
negative phase whiles CH3 of ethene appeared on the positive phase (refer to spectrum at 
Appendix H6). IR analysis showed peaks at 3343 cm-1, 2966 cm-1, 2873 cm-1, and 1627 cm-1 for 
the N-H, C-H and the C=O stretching respectively (refer to spectrum at Appendix H7). UV-Vis 
absorption of the compound in methanol was at 224 nm and 322 nm. GC/MS analysis of the 
compound in acetone produced molecular ion peak at m/z = 346.0 amu and a base peak at m/z = 
241.0 amu (refer to spectrum at Appendix H8). 
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The general procedure was followed, and 4-pyridine carboxaldehyde was used and the 
reaction stirred for 4 hours under nitrogen. The reaction was quenched with 20mL distilled water 
and filtered. Crystallization of the compound was done using pentane to afford a yellow crystal 
solid of compound 4f. 1H NMR of 4f in CDCl3 gave four doublet and two triplet peaks for the 
aromatic protons between 7.01-7.98 ppm and two N=CH on the pyridine was found between 
8.68-8.69 ppm. A doublet peak for N-H and N=C-H group at 8.50-8.44 ppm respectively. A 
doublet for the 11aH between 4.37- 4.39 ppm and a multiplet for N-CH2 between 3.67-3.84 ppm 
on the pyrrolidine ring. A two multiplet was recorded for the two CH2 groups on the pyrrolidine 
ring between 1.88-2.98 ppm (refer to spectra in Appendix I1, I2, and I3). 13C NMR gave 16 
expected peaks with characteristic peaks at 165.86 ppm for C=O, 158.86 and 155.39 ppm for the 
two C=N ppm. 9 carbon peaks were found between 120.93-150.54 ppm on the aromatic regions. 
And the C-11a peak showed at 55.52 ppm. The three CH2 groups on the pyrrolidine ring also 
produced peaks at 47.43 ppm, 26.15 ppm, and 23.55 ppm (refer to spectrum in Appendix I4). In 
DEPT-135 all quaternary carbons disappeared and N=CH appeared on the positive phase at 
155.39 ppm. 6 aromatic carbons were found on the positive phase between 120.94 -150.54 ppm 
and C-11a showed on the positive phase at 55.51 ppm. All the CH2 on the pyrrolidine ring 47.44 
ppm, 26.15 ppm and 23.55 ppm appeared on the negative phase (refer to spectrum at Appendix 
I5). IR analysis showed peaks at 3343 cm-1, 2966 cm-1 and 2873 cm-1, and 1625 cm-1 for the N-
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H, C-H and the C=O stretching respectively (refer to spectrum at Appendix I6). UV-Vis 
absorption of the compound in methanol was at 223 nm and 334 nm (refer to spectrum at 
Appendix I7). GC/MS analysis of the compound in acetone produced molecular ion peak at m/z 
= 319.0 amu and a base peak at m/z = 241.0 amu (refer to spectrum at Appendix I8).  
 
Figure 12: X-ray diffraction ORTEP analysis of compound 4f 
 
Figure 13: Crystals of compound 4f from pentane 
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Indole-3-carboxaldehyde was dissolved in DCM and reacted with 4-
dimethylaminopyridine (DMAP) at 0o C.  Di-tert-butyl dicarbonate solution in THF was added 
slowly and in dropwise using an addition funnel and was warmed at room temperature for 6 
hours. The reaction mixture was then quenched with 50 mL of water and the organic layer was 
separated. The organic layer was washed with 5% HCl and saturated NaCl. It was then dried 
(MgSO4), filtered and concentrated in a vacuum. The crude solid was purified by dissolving it in 
DCM followed by precipitation by adding hexanes and filtered with a fritted funnel. The filtered 
residue was washed with hexanes and dried in a vacuum to give compound 5 117. 1H NMR of 
compound 5 in CDCl3 gave a singlet for HC=O at 10.01 ppm, aromatic protons produced two 
doublet a singlet and a multiplet from 7.36-8.29 ppm and tert-butyl group CH3 produced 9 
protons at 1.69 ppm (refer to spectrum in Appendix J1, J2, and J3). 13C NMR gave 11 peaks 
with characteristic peaks at C=O 185.93, COO 148.86 ppm. Aromatic carbons were found 
between 115.26 ppm to 136.67 ppm. 85 ppm was recorded for C-O and CH3 appeared at 28.16 
ppm (refer to spectrum in Appendix J4). 
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(S,E)-11- [2-( Tert-butyl 3-formyl-1H-Indole-1-Carboxylate) Methylene Hydrazono] Pyrrolo 









O O     
The general procedure was followed, and tert-butyl 3-formyl-1H-indole-1-carboxylate 
was used, and the reaction stirred overnight under nitrogen. Flash column chromatography with 
(1:1 v/v) hexane/acetone was used, and the solvent was evaporated in vacuum followed by 
solidification the compound in pentane to afford a yellow solid of compound 7. 1H NMR of 
compound 7 in CDCl3 gave two doublets, a double doublet a triplet, a multiplet and a singlet 
peaks representing for the aromatic 9 protons between 6.99 ppm-8.26 ppm. A two-singlet peaks 
for N-H and N=C-H group at 8.64 ppm and 8.47 ppm respectively. A double doublet for the 
11aH between 4.40 ppm-4.41 ppm and a multiplet for N-CH2 between 3.69 ppm-3.83 ppm on 
the pyrrolidine ring. A multiplet was observed for N-CH2 on the pyrrolidine ring another 
multiplet was observed for the two CH2 groups on the pyrrolidine ring between 2.01 ppm-2.16 
ppm. A tert-butyl group occurred at 1.69 ppm as singlet (refer to spectra in Appendix K1, K2, 
and K3). 13C NMR gave 24 expected peaks with peaks at 166.12 ppm and 156.57ppm for C=O, 
152.30 ppm and 149.29 ppm for the two C=N ppm. 14 carbon peaks were found between 115.45 
ppm-136.97 ppm for the aromatic carbons. C-O carbon peak was observed at 84.89 ppm while 
the C-11a peak showed at 55.54 ppm while the three CH2 groups on the pyrrolidine ring also 
produced peaks at 47.46 ppm, 26.18 ppm, and 23.55 ppm. Also, tert-butyl group occurred at 
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28.25 ppm (refer to spectrum in Appendix K4 and K5). In 13C DEPT-135 all quaternary 
carbons disappeared and N=CH appeared on the positive phase at 152.33 ppm. 8 aromatic 
carbons were found instead of 9 on the positive phase between 114.67 ppm-132.44 ppm. This 
was because one of the carbons were the same. C-11a peak showed on the positive phase at 
55.54 ppm. All the CH2 on the pyrrolidine ring 47.47 ppm, 26.18 ppm, and 23.56 ppm appeared 
on the negative phase whiles tert-butyl group appeared on the positive phase (refer to spectrum 
in Appendix K6). IR analysis showed peaks at 3353 cm-1, 2977 cm-1, and 2879 cm-1, and 1627 
cm-1 for the N-H, C-H and the C=O stretching respectively (refer to spectrum in Appendix K7). 
UV-Vis absorption of the compound in methanol was at 235 nm and 350 nm. GC/MS analysis of 
the compound in acetone produced molecular ion peak at m/z = 457.0 amu and a base peak at m/z 
= 391.0 amu (refer to spectrum in Appendix K8). 
 
 









Procedures from118,119 was used with some modifications (tert-butyl 3-formyl-1H-indole-
1-carboxylate) methylene hydrazono PBD was reacted with potassium carbonate in a 20 mL 
mixture of MeOH/H2O and reflux for 30 minutes. The mixture was cooled down and washed 
with ether to afford white solid of compound 8. 1H NMR of compound 8 in C2D6OS gave two 
doublets, a double doublet a triplet, a multiplet and a singlet peaks representing for the aromatic 
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9 protons between 7.14 ppm-8.34 ppm. A two-singlet peaks for N-H and N=C-H group at 8.97 
ppm and 8.67 ppm respectively. A double doublet for the 11aH between 4.45 ppm-4.57 ppm and 
a multiplet for N-CH2 between 3.54 ppm-3.63 ppm on the pyrrolidine ring. A multiplet was 
observed for the two CH2 groups on the pyrrolidine ring between 1.94 ppm-2.03 ppm (refer to 
spectra in Appendix L1, L2, and L3). 13C NMR gave 18 peaks with peaks at 166.63 ppm for 
C=O, 154.66 pm and 153.92 ppm for the two C=N ppm. 11 carbon peaks were found between 
112.65 ppm-138.13 ppm for the aromatic carbons because three of the aromatic carbons were 
symmetric. C-11a peak showed at 55.56 ppm while the three CH2 groups on the pyrrolidine ring 
also produced peaks at 47.44, 26.30, and 23.66 ppm. (refer to spectrum in Appendix L4 and 
L5). In 13C DEPT-135 all quaternary carbons disappeared and N=CH appeared on the positive 
phase at 153.93 ppm. 7 aromatic carbons were found on the positive phase between 121.17 ppm-
132.62 ppm. C-11a peak showed on the positive phase at 55.56 ppm. All the CH2 on the 
pyrrolidine ring 47.44 ppm, 26.30 ppm and 23.66 ppm appeared on the negative phase (refer to 
spectrum in Appendix L6). IR analysis showed peaks at 3504 cm-1, 2917 and 2850 cm-1, and 
1617 cm-1 for the N-H, C-H and the C=O stretching respectively (refer to spectrum in Appendix 
L7). UV-Vis absorption of the compound in methanol was at 221 nm and 331 nm. GC/MS 
analysis of the compound in acetone produced molecular ion peak at m/z = 357.0 amu and a base 







Cancer Inhibition Activity 
PBD compound derivatives were determined for cytotoxicity on cancer cell lines. Using a 
single dose application, four of the compounds were evaluated on NCI-60 cell lines at the 
National Cancer Institute (refer to table 1). Screening of the compound was done at a 
concentration of 10 µM. 
In leukemia, cancer cell line K-562 had 11.05% inhibition on compound 4b. Less than 10% was 
observed for the rest of the compounds. Non- small cell lung cancer showed 16.41% inhibition 
on cell line HOP-92 for compound 4c and compound 4b also showed 13.44% inhibition. Colon 
cell line recorded less than 5% for all the compounds tested. Cell line SNB-75 for CNS showed 
20.93% and 24.99 % inhibition for compound 4a and 4b respectively. Melanoma cell line 
MALME-3M recorded 12.16% inhibition for compound 4a and cell line UACC-62 recorded 
8.29% inhibition for compound 4b. In ovarian cell line OVCAR-4, 10.62% inhibition were 
recorded for both compound 4a and 4b. Renal cell line 786-0 and UO-31, 15.43% and 16.16% 
was recorded for compound 4b respectively. In prostate cell line PC-3, 8.72% and 6.65% 
inhibition were recorded for compound 4b and 4c respectively. Breast cancer cell line T-47D 







Table 1: In vitro cytotoxicity data of PBD derivatives on NCI-60 cell lines 
                                                                           Growth Percent of PBD derivatives 
                       




































































































Enzyme Inhibition Kinetics 
Enzyme inhibition kinetics was done to determine the percentage inhibition and residual 
activity of the enzymes TEM-1, AmpC, and P99 lactamase was carried out in 20 mM MOPS 
buffer. 3μL (final concentration = 0.25, 0.2 and 0.20 nM for TEM-1, AmpC and P99 
respectively) of enzymes was used for the assay.  
 
Table 2: Residual activity (%) and percent inhibition of TEM-1 
Final concentration and volume of enzyme (TEM-1) = 3 μL (0.45 nM), 
Substrate (NCF) = 10 uL (100 μM),  
0.1 % BSA in MOPS buffer = 562 μL (0.02 mM, pH – 7.5), 




V˳ ± SD (ΔA, s-1) × 
10-3 
Initial Rate +Inhibitor 







     (%) 
   
 4a 5.074 ±0.029 1.010±0.023 80.4 19.6 
 4b 5.074 ±0.029 6.532±0.018 100 0 
 4c 5.074 ±0.029 0.535±0.019 89.8 10.2 
 4d 5.074 ±0.029 2.531±0.017 50.2 49.8 
 4e 5.074 ±0.029 6.032±0.015 100 0 
 4f 5.074 ±0.029 1.512±2.214 89.0 21.0 
 8 5.074 ±0.029 6.232±0.017 100 0 
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Table 3: Residual activity (%) and percent inhibition of AmpC 
Final concentration and volume of enzyme (AmpC) = 3 μL (0.45 nM), 
Substrate (NCF) = 10 uL (100 μM),  
0.1 % BSA in MOPS buffer = 562 μL (0.02 mM, pH – 7.5), 
Inhibitor (in 3% acetone) = 20 μL (500 μM) 
 
 
Table 4: Residual activity (%) and percent inhibition of P99 
Final concentration and volume of enzyme (p99) = 3 μL (0.45 nM), 
Substrate (NCF) = 10 uL (100 μM),  
0.1 % BSA in MOPS buffer = 562 μL (0.02 mM, pH – 7.5), 




V˳ ± SD (ΔA, s-1) × 
10-3 
Initial Rate +Inhibitor 







      (%) 
 4a 
 
8.718±0.018 8.526±0.212 95.56 4.44 
 4c 8.718±0.018 7.824±0.128 88.45 11.55 





V˳ ± SD (ΔA, s-1) × 
10-3 
Initial Rate +Inhibitor 







      (%) 
 4d 5.184±0.025 4.824±0.028 92.03 7.97 
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The results of the inhibition studies conducted on TEM-1 shows that compound 4d had the 
highest inhibition of 49.8% followed by compound 4f and 4a at 20.99% and 19.6% respectively. 
Compound 4c recorded 10% inhibition and no inhibition was recorded for compound 4b, 4e, and 
4g. No inhibition was recorded for compound 4b, 4e and 8 because they did not produce a 
supernatant solution when the enzyme was added. The other results from lactamase AmpC also 
showed that compound 4c had the highest inhibition of 11.55% but there was no inhibition 
recorded for compound 4d. On lactamases p99, compound 4d only showed 7.97% inhibition. In 
summary, only compound 4d was a selective inhibitor of the lactamase TEM-1.  
 
Cannabinoid Binding Activity 
Preliminary cannabinoid binding activity was conducted on compound 4a and it was 
found out that the compound had 46.8% binding affinity to cannabinoid receptor 1 and 77.4% 
binding activity to cannabinoid receptor 2. However, a comprehensive binding activity of the 










EXPERIMENTAL SECTION  
Materials and General Methods 
 L-proline, isatoic anhydride and other chemicals were purchased and used without further 
purification unless otherwise stated. 
1H NMR, 13C NMR, GC-MS, IR spectroscopy and X-ray crystallography were used for 
the characterization of the synthesized compounds. All the NMR spectra were executed with 
JEOL-NMR Eclipse-400 MHz spectrophotometer and the coupling constants value (J) was 
recorded in Hz. The patterns of splitting resonance were presented as singlet (s), doublet (d), 
triplet (t), and multiplet (m). Shimadzu 1R Prestige-21 FT-IR was used for all IR spectra. The 
melting point of the compounds was done using Cambridge Melt-Temp apparatus. Fragments of 
the compounds produced molecular ion and was performed with Shimadzu GC-MS 2010 device. 
Thin layer chromatography and column chromatography were used to purify the compounds. X-
ray crystallography was also used for the crystal structure determination of the compounds 

















Dilactam 1 was synthesized using formally reported methods with some alterations. 
Isotaic anhydride (10.0 g, 61.34 mmol) and L-proline (7.06 g, 61.34 mmol) was reacted using 
N,N-dimethylformamide (50 mL) and the reaction mixture was heated to about 155 ˚C for 5 h. 
The solvent was then removed in vacuo after cooling was done at room temperature and the 
residue was finally taken up in water. A solid of white color with gray was obtained after drying. 
Recrystallization was done using acetone/DMF (v/v 10:1) which gave 10.87 g of pure compound 
1 as off-white crystals. Yield: 83.0 %; m.p: 223-225 oC; [𝛼]
25
𝐷
 = + 512 o (c 0.5, MeOH); 1H-
NMR (400 MHz, DMSO-d6):  = 1.76-1.95 (m, 3H), 3.42-3.48 (m, 1H), 3.56-3.61 (m, 1H), 4.10 
(d, J = 8 Hz, 1H), 7.12 (dd, J = 12, 4 Hz, 1H), 7.20-7.24 (m, 1H), 7.49-7.51 (m, 1H), 7.82 (dd, J 
= 12, 8Hz, 1H), 10.51 (s, 1H); 13C-NMR (100 MHz, DMSO-d6):  = 23.6, 26.3, 47.4, 56.8 (C-
11a), 121.8, 124.4, 127.1, 130.8, 132.6, 136.9, 165.0 (CO), 171.3 (CO); UV λmax (MeOH): 222, 
231, 235 nm. IR (KBr); 3218 (N-H), 2969 (C=O), 2879, 1693 (C=O), 1619 (C=O), 1479, 1444, 
1413, 1285, 1259, 1162, 757, 700. GC-MS (70 eV) m/z (%): 216 (10) [M+], 119 (14), 92 (20), 70 














A mixture of 1 (33.35 g, 154 mmol) and Lawesson’s reagent (31.11 g, 77 mmoL) in THF 
(350 mL) was stirred over night at room temperature. The solvent was then evaporated in vacuo 
to produce a solid yellow residue which was washed with toluene and further washed with cold 




 = + 762 o (c 0.5, CHCl3); 
1H-NMR (400 MHz, DMSO-d6):  = 1.76-2.00 (m, 1H), 1.98-
2.09 (m, 2H), 2.88 (d, J = 5.9 Hz, 1H), 3.31-3.51 (m, 3H), 3.56-3.61 (m, 1H), 4.28 (d, J = 6.2 Hz, 
1H), 7.29 (d, J = 8.1 Hz, 1H), 7.33-7.37 (m, 1H), 7.58 (t, J = 7.7 Hz, 1H), 7.83 (dd, J = 7.7, 1.5 
Hz, 1H); 13C-NMR (100 MHz, DMSO-d6):  = 23.39, 26.12, 47.30, 55.53 (C-11a), 119.88, 
122.84, 125.30, 131.34, 132.45, 137.92, 166.24 (CO). UV λmax (MeOH): 209, 212, 231 nm. IR 
(KBr): 3456 (N-H), 2969 (C-H), 1739, 1619 (C=O), 1479, 1367, 1216, 759. GC/MS (70 eV) m/z 














 Compound 2 (23.2g, 100 mmoL) was reacted with 98o/o hydrazine monohydrate (15.0 g, 
14.6 mmoL) in ethanol (300 mL) and stirred for 15 h at room temperature. Water was added to 
the residue to obtain the product after the solvent was evaporated in vacuum. The precipitate was 
then dried and washed with diethyl ether to give 18.34 g of compound 3 as off-white solid.37 
Yield: 80.0 %; m.p. : 178-180 o C; [𝛼]
25
𝐷
 = + 552 o (c 0.5, MeOH);  1H-NMR (400 MHz, CDCl3): 
 = 1.931−2.13 (m, 4H), 2.72 (s, 1H), 3.61−3.70 (m, 2H), 4.2 (s, 1H), 6.83 (d, J = 8 Hz, 1H), 
7.05 (t, J = 7.3 Hz, 1H), 7.31 (t, J = 15.4 Hz, 2H), 7.86 (d, J = 7.7 Hz, 1H); 13C-NMR (100 MHz, 
CDCl3):  δ = 23.4, 26.1, 47.3, 55.5 (C-11a), 119.7, 123.0, 125.4, 131.5, 132.5, 137.8, 152.2, 
166.2 (CO). UV λmax (MeOH): 219, 266, 311 nm. IR (KBr): 3261(N-H), 2948 (C-H), 2877, 
1710, 1631 (C=O), 1471, 1394, 1251, 1201, 1160, 757, 703, 597. GC/MS (70 eV) m/z (%): 232 
(7) [M+], 108 (6), 70 (100), 68 (6). 
 
 
General method for synthesis of (S,E)-11-[2-(Arylmethylene)Hydrazono] Pyrrolo [2,1-c] [1,4] 
Benzodiazepine (4a-f) 
To a solution of compound 3 (690 mg, 3 mmoL) in anhydrous methanol (20 mL) was added 
aldehyde (10 mmoL). 3Aº molecular sieves (2.0 g) was also added and stirred at room 












Benzaldehyde (1.02 mL, 10 mmoL) was added and stirred overnight. Extraction was 
done with chloroform/isopropanol in ratio (2:1) using (3×20 mL). Anhydrous sodium sulfate was 
used to absorb excess moisture in the organic layer. The solvent was then removed in vacuo and 
wash with diethyl ether, filtered and dried to afford an off-white solid of compound 4a. The final 
product was purified using crystallization from isopropanol to yield colorless needle shape 
crystals. Yield 497 mg (72%); mp 198-200 o C; [𝛼]
25
𝐷
 = + 50 o (c 0.5, CHCl3): 
1H-NMR (500 
MHz, CDCl3):  =2.02-2.07 (m, 3H), 3.00 (d, J = 11.4 Hz, 1H), 3.68-3.83 (m, 2H), 4.38 (d, J = 
6.2 Hz, 1H), 6.99 (d, J = 8 Hz, 1H), 7.17 (t, J = 15 Hz, 1H), 7.43 (s, 4H), 7.79 (s, 2H), 7.96 (d, J 
= 8Hz, 1H), 8.48 (s, 1H), 8.53 (s, 1H); 13C-NMR (100 MHz, CDCl3):  = 23.56, 26.15, 47.42, 
55.52 (C-11a), 120.77, 123.86, 126.44, 128.22, 128.85, 130.86, 131.49, 132.48, 134.57, 136.80, 
157.63, 157.83, 166.06 (CO). UV λmax (MeOH): 223, 319 nm. IR (KBr): 3351, 2981, 2879, 2370, 
1963, 1710, 1627 (C=O), 1471, 1400, 1295, 1097, 964, 831, 757, 692, 630. GC/MS (70 eV) m/z 














4-Methoxybenzaldehyde (1.22 mL, 10 mmoL) was used and the reaction was stirred for 6 
hours. The solution was filtered and wash with diethyl ether to afford a light yellow solid 469.2 
mg of compound 4b. The final product was purified using crystallization from isopropanol to 
yield colorless needle shape crystals. Yield 68%; mp 212-214 o C. [𝛼]
25
𝐷
 = + 40 o (c 0.5, CHCl3):  
1H-NMR (400 MHz, CDCl3):  =1.88-2.130 (m, 3H), 2.99-3.0 (m, 1H), 3.69-3.84 (m, 5H), 4.37 
(d, J = 8 Hz, 1H), 6.98 (q, J = 19.76, 18.7 Hz,  3H), 7.15 (t, J = 15.5 Hz, 1H), 7.42 (t, J = 15.4 
Hz, 1H), 7.73 (d, J = 8 Hz, 2H), 7.95 (d, J = 4 Hz, 1H), 8.42 (s, 1H), 8.52 (s, 1H); 13C-NMR (100 
MHz, CDCl3):  = 23.55, 26.11, 47.40, 55.028 (C-11a, CH3), 114.29, 120.72, 123.67, 126.34, 
127.32, 129.84, 131.46, 132.45, 136.96, 156.98, 157.38, 161.83, 166.11 (CO). UV λmax (MeOH): 
221, 325 nm. IR (KBr): 3259, 2958, 2854, 2350, 1706, 1619 (C=O), 1517, 1469, 1394, 1224, 
1120, 927, 827, 759, 700. GC/MS (70 eV) m/z (%): 348 (65) [M+], 241 (100), 160 (8), 145 (10), 















4-Flurobenzaldehyde (1.22 mL, 10 mmoL) was used and the reaction was stirred for 4 
hours followed by quenching with 20 mL distilled water and filtered to give a white solid 505.8 
mg of compound 4c. The final product was purified using crystallization from hexane/acetone to 
yield yellow rod shape crystals. Yield 73.3%; mp 205-207 o C [𝛼]
25
𝐷
 = + 30 o (c 0.5, CHCl3): 
1H-
NMR (400 MHz, CDCl3):  =2.00-2.13 (m, 3H), 2.96-3.0 (m, 1H), 3.68-3.81 (m, 2H), 4.38 (d, J 
= 5.9 Hz, 1H), 7.00 (d, J = 4 Hz, 1H), 7.01-7.19 (m, 3H), 7.42 (t, J = 15.4 Hz, 1H), 7.78 (t, J = 
9.9 Hz, 2H), 7.96 (d, J = 8 Hz, 1H), 8.45 (s, 1H,) 8.49 (s, 1H); 13C-NMR (100 MHz, CDCl3):  = 
23.55, 26.14, 47.42, 55.50 (C-11a), 115.94, 116.17, 120.76, 123.91, 126.46, 130.05, 130.14, 
131.50, 132.49, 136.74, 156.52, 157.65, 161.83, 166.04 ((C=O). UV λmax (MeOH): 222, 236, 313 
nm. IR (KBr): 2348, 1710, 1625 (C=O), 1508, 1471, 1396, 1270, 1226, 1155, 833, 755, 700, 





 (S,E)-11-[2-4-(4-Formylphenyl) Morpholine Methylene Hydrazono] Pyrrolo [2,1-c] [1,4] 










4-(4-Formylphenyl) morpholine (1.91g, 10 mmoL) was used and the reaction was stirred 
overnight under nitrogen gas. Flash column chromatography using hexane/acetone (v/v) 1:1 was 
used and the solvent was evaporated in vacuo. Crystallization of the compound was done using 
pentane to afford a yellow rod shape crystal 358.8 mg of compound 4d. Yield 52.0%; mp ;198-
200 o C; C [𝛼]
25
𝐷
 = +  46 o (c 0.5, CHCl3):
1H-NMR (400 MHz, CDCl3):  =1.73-2.16 (m, 3H), 
2.97-3.01 (m, 1H), 3.25 (s, 4H), 3.68-3.86 (m, 6H), 4.38 (d, J = 5.8 Hz, 1H), 6.91 (d, J = 8.8 Hz,  
2H), 6.98 (d, J = 8 Hz, 1H), 7.16 (t, J = 16.1 Hz, 1H), 7.42 (t, J = 15.4 Hz, 1H), 7.7 (d, J = 8.8 
Hz, 2H), 7.96 (d, J = 8 Hz, 1H), 8.40 (s, 1H), 8.52 (s, 1H); 13C-NMR (100 MHz, CDCl3):  = 
23.55, 26.14, 47.40, 48.21, 55.50 (C-11a), 66.79, 114.68, 120.68, 123.60, 125.59, 126.31, 
129.62, 131.47, 132.43, 137.04, 152.95, 156.65, 157.59, 166.14 (C=O). UV λmax (MeOH): 235, 
350 nm. IR (KBr): 3259, 2956, 2854, 2350, 1706, 1619 (C=O), 1517, 1469, 1394, 1224, 1120, 
927, 827, 759.82, 700. GC-MS (70 eV) m/z (%): 403 (1) [M+], 355 (8), 327 (9), 281 (49), 253 













  4-Ethylbenzaldehyde (1.37 mL, 10 mmoL) was used and stirred overnight under nitrogen 
and evaporation of the solvent was done in vacuo. Crystallization of the compound was done 
using  pentane to give a yellow solid rod shape crystal of 499.6 mg of compound 4e. Yield 
72.4%; mp; 168-170 o C; C [𝛼]
25
𝐷
 = +  54 o (c 0.5, CHCl3): 
1H-NMR (400 MHz, CDCl3):  =1.26 
(t, J = 15 Hz, 4H), 2.02-2.15 (m, 3H), 2.66-2.72 (m, 2H), 2.98-2.99 (m, 1H), 3.64-3.84 (m, 2H), 
4.38 (d, J = 5.6 Hz, 1H), 7.00 (d, J = 4 Hz, 1H), 7.17 (t, J = 16.1 Hz, 1H), 7.26 (d, J = 8.6 Hz,  
1H), 7.43 (t, J = 15.4 Hz,  1H), 7.71 (d, J = 8 Hz, 2H), 7.97 (d, J = 9.5 Hz, 1H), 8.46 (s, 1H), 
8.52(s,1H); 13C-NMR (100 MHz, CDCl3):  = 15.50, 23.56, 26.15, 29.03, 47.43, 55.52 (C-11a), 
120.73, 126.38 , 128.31, 128.42, 131.47, 132.09, 132.48, 136.89, 147.59, 157.31, 157.68, 166.10 
( C=O). UV λmax (MeOH): 224, 322.  IR (KBr): 3733, 3598, 3343, 3261, 2966, 2873, 2360, 2341, 
1625 (C=O), 1469, 1396, 1270, 1160, 970, 831, 752, 669. GC-MS (70 eV) m/z (%): 403 (1) 














4-pyridine carboxaldehyde (0.95 mL, 10 mmoL) was used and the reaction stirred for 4 
hours under nitrogen. The reaction was quench with 20 mL distilled water and filtered. 
Crystallization of the compound was done using pentane to afford a yellow crystal solid 436.8 
mg of compound 4f. Yield 63.3% mp; 242-244 oC; C [𝛼]
25
𝐷
 = +  56 o (c 0.5, CHCl3):  
1H-NMR 
(400 MHz, CDCl3):  =1.88-2.10 (m, 3H), 2.98 (d, J = 5.1 Hz, 1H), 3.67-3.84 (m, 2H), 4.39 (d, J 
= 5.8 Hz, 1H), 7.02 (d, J = 4 Hz, 1H), 7.2 (t, J = 15 Hz, 1H), 7.45 (t, J = 15.4 Hz, 1H), 7.63 (d, J 
= 4Hz, 2H), 7.97 (d, J = 8Hz, 1H), 8.43 (s, 1H), 8.5 (s, 1H), 8.67  (d, J = 4 Hz, 2H); 13C-NMR 
(100 MHz, CDCl3):  = 23.55, 26.15, 47.43, 55.52 (C-11a), 120.92, 121.82, 124.32, 126.67, 
131.53, 132.55, 136.33, 141.65, 150.54, 155.39, 158.86, 165.86 (C=O). UV λmax (MeOH): 223, 
334 nm.  IR (KBr): 3276, 2977, 2879, 2360, 2341, 1625 (C=O), 1585, 1400, 1220, 1097, 991, 
755, 530. GC-MS (70 eV) m/z (%): 319 (14) [M+], 281(4), 241 (100), 207 (9), 172 (11), 145 












Indole-3-carboxaldehyde (0.44 g, 3 mmoL) in 50 mL of DCM was reacted with 4-
dimethylaminopyridine (DMAP) (122 mg, 1 mmoL) at 0 ̊ C (ice-bath). Di-tert-butyl dicarbonate 
(1.0M in THF) solution (2.76 mL, 12 mmoL) was added slowly and in drop wise using an 
addition funnel. It was then allowed to warm at room temperature for 6 hours. The reaction 
mixture was then quenched with 50 mL of water and the organic layer was separated. The 
organic layer was washed with 5% HCl (2.0 × 30 mL) and saturated NaCl (50 mL), dried 
(MgSO4), filtered and concentrated in a vacuum. The crude solid was purified by dissolving it in 
DCM (10 mL) followed by precipitation by adding hexanes (30 mL) and filtered with fritted 
funnel. The filtered residue was be washed with hexanes and dried in a vacuum to give 0.34 g of 
tert-butyl 3-formyl-1H-indole-1-carboxylate. Yield: 78.07 %;  1H-NMR (400 MHz, CDCl3):  = 
1.7 (s, 9H), 7.34-7.42 (m, 2H ), 8.14 (d, J = 4 Hz, 1H), 8.23 (s, 1H ), 8.29 (d, J = 4 Hz, 1H), 10.1 
(s, 1H); 13C-NMR (100 MHz, CDCl3):  = 28.17, 85.76, 115.26, 121.60, 122.21, 124.69, 126.17, 
136.02, 136.67, 148.86 (C=O), 185.94. UV λmax (MeOH): 215, 239, 288 nm. 
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(S,E)-11- [2-( Tert-Butyl 3-Formyl-1H-Indole-1-Carboxylate) Methylene Hydrazono] Pyrrolo 








O O  
   Tert-butyl 3-formyl-1H-indole-1-carboxylate (2.46 g, 10 mmoL) was used and the 
reaction stirred overnight under nitrogen. Flash column chromatography using hexane/acetone 
(v/v) 1:1 was used and the solvent was evaporated in vacuo followed by solidification the 
compound in pentane to afford a yellow solid 517.5 mg of compound 7. Yield 75.0% mp; 253-
255 o C; C [𝛼]
25
𝐷
 = + 32 o (c 0.5, CHCl3):  
1H-NMR (400 MHz, CDCl3):  =1.53-1.75 (s, 9H), 
2.0-2.16 (m, 4H), 3.0-3.03 (m, 1H), 3.58-3.83 (m, 2H), 4.43 (d, J = 5.4 Hz, 1H), 7.0 (d, J = 8 Hz, 
1H), 7.20 (t, J = 8 Hz, 1H), 7.36-7.52 (m, 3H), 7.96 (t, J = 15.4 Hz, 2H), 8.26 (d, J = 1.4 Hz, 
1H), 8.47 (s, 1H), 8.64 (s, 1H). 13C-NMR (100 MHz, CDCl3):  = 23.55, 26.18, 28.25 47.46, 
55.54 (C-11a), 84.89, 115.45, 117.24, 121.07, 122.34, 123.74, 125.17, 125.60, 126.35, 127.45, 
131.23, 132.53, 136.24, 136.97, 149.29, 152.30, 156.57, 166.13 (C=O). UV λmax (MeOH): 211, 
323 nm. IR (KBr): 3353, 2977, 2879, 2360, 2341, 1735, 1627 (C=O), 1540, 1469, 1365, 1321, 
1234, 1155, 1093, 754, 669, 597. GC-MS (70 eV) m/z (%): 457 (1) [M+], 406 (78), 391 (100), 














(Tert-butyl 3-formyl-1H-indole-1-carboxylate) methylene hydrazono PBD (460 mg, 1 
mmoL) was reacted with potassium carbonate (979 mg, 7.1 mmoL) in a 20 mL mixture of 
MeOH/H2O and reflux for 30 minutes. The mixture was cooled down and washed with ether to 
afford 802. 8 mg white solid of compound 8. Yield 75.0% mp; 242-243 o C; C [𝛼]
25
𝐷
 = + 56 o (c 
0.5, CHCl3):  
1H-NMR (400 MHz, CDCl3):  =1.94-2.03 (m, 3H), 2.85 (d, J = 6.1 Hz, 1H), 3.54-
3.63 (m, 2H), 4.46 (d, J = 4 Hz, 1H), 7.16-7.18 (m, 3H), 7.36-7.38 (m, 3H), 7.76 (d, J = 1.8 Hz, 
2H), 7.96 (s, 1H), 8.34 (d, J = 17.2 Hz, 1H), 8.97 (s, 1H); 13C-NMR (100 MHz, CDCl3):  = 
23.66, 26.30, 47.44, 55.56 (C-11a), 112.65, 121.17, 122.40, 122.74, 123.01, 123.19, 131.02, 
132.61, 137.97, 138.12, 153.92, 154.66, 165.63 (C=O). UV λmax (MeOH): 221, 331 nm. IR 
(KBr): 3504, 2917, 2850, 2337, 1751, 1617 (C=O), 1371, 1240, 1052, 877, 746, 608. GC-MS 
(70 eV) m/z (%): 357 (2) [M+], 355 (6), 327 (9), 281 (52), 253 (18), 249 (7), 207 (100), 191 (15), 








CONCLUSIONS AND FUTURE WORK 
Conclusions 
In the research, seven novel compounds were synthesized from dialactam 1 a as biological active 
molecule. The PBD derivatives synthesized were: (S,E)-11-[2-(phenylmethylene)hydrazono] 
pyrrolo [2,1-c] [1,4] benzodiazepine, (S,E)-11-[2-(4-methoxyphenyl) methylene hydrazono] 
pyrrolo [2,1-c] [1,4] benzodiazepine, (S,E)-11-[2-(4-fluorophenyl) methylene hydrazono] pyrrolo 
[2,1-c] [1,4] benzodiazepine, (S,E)-11-[2-4-(4-formylphenyl)morpholine methylene hydrazono] 
pyrrolo [2,1-c] [1,4] benzodiazepine,  (S,E)-11-[2-(4-ethylphenyl) methylene hydrazono] pyrrolo 
[2,1-c] [1,4] benzodiazepine, (S,E)-11-[2-(4-pyridine) methylene hydrazono] pyrrolo [2,1-c] 
[1,4] benzodiazepine and  (S,E)-11- [2-(indole) methylene hydrazono] pyrrolo [2,1-c] [1,4] 
benzodiazepine.  
        The highest inhibition growth for cancer cell was observed for CNS on cell line SNB-75 
with compound 4b at 25.0% followed by compound 4a at 20.90%. Low inhibition was observed 
for the rest of the compounds on the cancer cells which was less than 20%. Results from the 
enzyme kinetics showed that compound 4d has a good inhibition on TEM-1 at 49.8%. This 
shows that compound 4d has the best potentials of being non-β-lactam β-lactamase inhibitor on 
TEM-1 of the serine lactamase class A. This is because it had a better interaction with the active 
site residue of the enzyme. There was no significant inhibition on the AmpC lactamase that was 
tested on the compounds also a specific test of compound 4d on lactamase P99 did not also show 
any significant inhibition. The poor inhibitory activities of other PBD derivatives could have 
been because of poor solubility of the compounds in the solvent that was used. Another reason 
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for the poor enzyme inhibition result could also be attributed to the bulkiness of the PBD 
derivatives so the active site of the enzyme was unavailable for better interaction with the ligand. 
The cannabinoid receptors CB1 and CB2 are have become a vital subject for research in a 
variety of neurological and immunological processes. With CB1 expressing predominately in the 
brain and peripheral neurons, and CB2 expressing in the immune cells, preliminary results of 
cannabinoid binding activity showed that compound 4a showed high selective binding to CB2 at 
77.4% than CB1 at 46.8%. however, to determine whether to the binding of the ligand to the 
receptor is agonist or antagonist is in the pipeline. This could be a promising ligand for the 
cannabinoid receptor in the future. 
 
Future Work 
We will focus on evaluating the cannabinoid binding receptor activity for the rest of the 
compounds synthesized. Compound 4a had a good binding affinity to CB2, which could be due 
to an activating group attached to PBD hydrazone, which had a better interaction with G-couple 
proteins of the cannabinoid receptor. It will be interesting to know how the other derivatives of 
the PBD which has deactivating, and bulky groups will interact with cannabinoid receptors to 
establish structure-activity relationship. We will also focus on introducing functional groups on 
the PBD rings to improve the solubility of the PBD analogs for better interactions with the 
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Appendix E7: UV-Vis Spectrum for Compound 4b 
 





















Appendix E8: GC/MS Spectrum for Compound 4b 
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Appendix F8: UV-Vis Spectrum for Compound 4c 
 





















Appendix F9: GC/MS Spectrum for Compound 4c 
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Appendix G8: GC/MS Spectrum for Compound 4d 
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Appendix H8: GC/MS Spectrum for Compound 4e 
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Appendix I7: UV-Vis Spectrum for Compound 4f 
 





















Appendix I8: GC/MS Spectrum for Compound 4f 
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Appendix K8: GC/MS Spectrum for Compound 7 
 
 






























































Appendix L8: UV- Vis Spectrum for Compound 8 
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